AssetMark’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.48K Sell
99
-35
-26% -$1.89K ﹤0.01% 2745
2026
Q2
$7.31K Buy
134
+90
+205% +$4.74K ﹤0.01% 2566
2026
Q1
$2.09K Sell
44
-4
-8% -$211 ﹤0.01% 2839
2025
Q4
$2.52K Sell
48
-1
-2% -$60 ﹤0.01% 2706
2025
Q3
$3.18K Buy
49
+6
+14% +$344 ﹤0.01% 2490
2025
Q2
$2.09K Buy
43
+32
+291% +$1.24K ﹤0.01% 2417
2025
Q1
$374 Sell
11
-4
-27% -$170 ﹤0.01% 2462
2024
Q4
$590 Buy
+15
New +$708 ﹤0.01% 2347
2024
Q3
– Sell
-4
Closed -$216 – 2278
2024
Q2
$216 Sell
4
-7
-64% -$405 ﹤0.01% 2001
2024
Q1
$750 Buy
+11
New +$787 ﹤0.01% 1695
2022
Q2
– Sell
-55
Closed -$3K – 1504
2022
Q1
$3K Buy
+55
New +$3.45K ﹤0.01% 1350

Other funds holding CRSP

AssetMark's CRSP Position: Q3 2026 in Review

AssetMark reduced its CRISPR Therapeutics (CRSP) stake by 26% in Q3 2026, selling an estimated $1.89K and leaving 99 shares worth $5.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

AssetMark first reported a position in CRSP in Q1 2022 and has held it in 11 quarters since. The position peaked at $7.31K in Q2 2026. 422 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • AssetMark held 99 shares of CRISPR Therapeutics worth $5.48K as of Q3 2026.
  • AssetMark sold 35 CRISPR Therapeutics shares in Q3 2026, an estimated $1.89K.
  • CRISPR Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2745 holding.
  • AssetMark first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • AssetMark's CRISPR Therapeutics position peaked at $7.31K in Q2 2026.
  • 422 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.